Compensation award — excluded from discretionary-purchase analysis.
Signed May 20, 2026 · Updated May 20, 2026
The Department of Defense placed a delivery order for $2.2K of Pfizer's CYKLOKAPRON on May 20, 2026. This is a routine purchase under an existing contract open to all bidders, part of $652K in similar awards over the past year.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
$2,246
Actual federal dollars obligated to date on this award
$2,246
A maximum, not earned revenue
$652K across 10 awards
Obligations to date on awards newly signed in the last 12 months, mapped to this company
83.2% from the largest awarding agency
Share of T12M mapped obligations
#9 of 10 mapped awards by obligations
Within the awards OQRO has ingested
0.00% of FY2021 revenue ($81.3B)
T12M mapped obligations ÷ revenue the company reported in its 10-K. A size comparison: obligations are not revenue and are usually earned over several years
verified alias
Exact identifier > verified alias > manual override
Compensation award — excluded from discretionary-purchase analysis.
33K → 31K shares held−6% of their stake
Pfizer's SVP & Controller sold $51K of Pfizer shares. Nobody planned it ahead of time.
Compensation award — excluded from discretionary-purchase analysis.